Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adc Therapeutics Sa (NY: ADCT )

4.340 -0.100 (-2.25%)
Official Closing Price Updated: 7:00 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 323,499
Open 4.440
Bid (Size) 4.200 (15)
Ask (Size) 4.850 (1)
Prev. Close 4.440
Today's Range 4.210 - 4.510
52wk Range 0.3599 - 6.040
Shares Outstanding 76,721,543
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
From ADC Therapeutics SA
Via GlobeNewswire

Performance

YTD
+156.80%
+156.80%
1 Month
+3.33%
+3.33%
3 Month
+62.55%
+62.55%
6 Month
+520.00%
+520.00%
1 Year
+123.71%
+123.71%

More News

Read More
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
From ADC Therapeutics SA
Via GlobeNewswire
A Preview Of ADC Therapeutics's Earnings
Via Benzinga
ADC Therapeutics - Time For A Turn-Around?
Via Talk Markets
Dollar Tree Reports Weak Earnings, Joins Tesla, Arcos Dorados And Other Big Stocks Moving Lower On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
From ADC Therapeutics SA
Via GlobeNewswire
Analyst Expectations for ADC Therapeutics's Future
Via Benzinga
Earnings Scheduled For March 13, 2024
Via Benzinga
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
From ADC Therapeutics SA
Via GlobeNewswire
Alaska Air To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
The 3 Biotech Stocks That Could Make Your February Unforgettable
Via InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in February 2024
Via InvestorPlace
ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
Why BEST Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023
From ADC Therapeutics SA
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.